Therapeutic efficacy of intestinal and multivisceral transplantation: Survival and nutrition outcome

被引:16
作者
Matarese, Laura E.
Costa, Guilherme
Bond, Geoffrey
Stamos, June
Koritsky, Darlene
O'Keefe, Stephen J. D.
Abu-Elmagd, Kareem
机构
[1] UMPC Montefiore, Intestinal Rehabil & Transplantat Ctr, Thomas E Starzl Transplantat Inst, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Med Ctr, Div Gastroenterol & Hepatol, Pittsburgh, PA USA
关键词
QUALITY-OF-LIFE; SMALL-BOWEL TRANSPLANTATION; HOME PARENTERAL-NUTRITION; SERUM CITRULLINE; PLASMA CITRULLINE; MANAGEMENT; RECIPIENTS; ALLOGRAFTS; REJECTION; MARKER;
D O I
10.1177/0115426507022005474
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
The clinical introduction of intestinal transplantation has added a new dimension and offered a valid therapeutic option for patients with irreversible intestinal failure. In the year 2000, the Center for Medicare & Medicaid Services (CMS) recognized intestinal, combined liver-intestinal, and multivisceral transplantation as the standard of care for patients with irreversible intestinal and parenteral nutrition (PN) failure. Accordingly, the indications for the procedure are currently limited to those who develop life-threatening PN complications. However, a recent improvement in survival similar to other solid organ transplant recipients should justify lifting the current restricted criteria, and the procedure should be considered before the development of PN failure. Equally important is the awareness of the recent evolution in nutrition management and outcome after transplantation. Early and progressive enteral feeding using a complex polymeric formula is safe and effective after successful transplantation. Full nutrition autonomy is universally achievable among most intestinal and multivisceral recipients, with enjoyment of unrestricted oral diet. Such a therapeutic benefit is commonly maintained. among long-term survivors, with full rehabilitation and restoration of quality of life.
引用
收藏
页码:474 / 481
页数:8
相关论文
共 57 条
[1]   Clinical intestinal transplantation: New perspectives and immunologic considerations [J].
Gruessner, RWG .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1998, 186 (05) :525-527
[2]  
Abu-Elmagd K, 2001, ANN SURG, V234, P404, DOI 10.1097/00000658-200109000-00014
[3]  
Abu-Elmagd K. M., 2005, THERAPY, V2, P853
[4]  
Abu-Elmagd Kareem, 2002, Adv Surg, V36, P65
[5]   Evolution of clinical intestinal transplantation: Improved outcome and cost effectiveness [J].
Abu-Elmagd, KM ;
Reyes, J ;
Fung, JJ ;
Mazariegos, G ;
Bueno, J ;
Janov, C ;
Colangelo, J ;
Rao, A ;
Demetris, A ;
Starzl, TE .
TRANSPLANTATION PROCEEDINGS, 1999, 31 (1-2) :582-584
[6]   Intestinal transplantation for short bowel syndrome and gastrointestinal failure: Current consensus, rewarding outcomes, and practical guidelines [J].
Abu-Elmagd, KM .
GASTROENTEROLOGY, 2006, 130 (02) :S132-S137
[7]  
ABUELMAGD K, 1994, J AM COLL SURGEONS, V179, P385
[8]  
ABUELMAGD K, 1992, TRANSPLANT P, V24, P1243
[9]   Plasma citrulline: A marker of enterocyte mass in villous atrophy-associated small bowel disease [J].
Crenn, P ;
Vahedi, K ;
Lavergne-Slove, A ;
Cynober, L ;
Matuchansky, C ;
Messing, B .
GASTROENTEROLOGY, 2003, 124 (05) :1210-1219
[10]   FUNCTIONAL-ASPECTS OF SMALL-BOWEL TRANSPLANTATION IN RATS [J].
DEBRUIN, RWF ;
HEINEMAN, E ;
JEEKEL, J ;
MEIJSSEN, MAC ;
LINDEMANS, J ;
BONTHUIS, F ;
MARQUET, RL .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1992, 27 (06) :483-488